Compare SLGN & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLGN | BLLN |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.6B |
| IPO Year | 1994 | 2025 |
| Metric | SLGN | BLLN |
|---|---|---|
| Price | $39.68 | $89.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $51.45 | ★ $128.29 |
| AVG Volume (30 Days) | ★ 824.0K | 654.6K |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | 4.65 | ★ 103.40 |
| EPS | ★ 2.30 | 0.81 |
| Revenue | ★ $4,489,927,000.00 | $305,112,000.00 |
| Revenue This Year | $4.16 | $51.66 |
| Revenue Next Year | $1.86 | $24.74 |
| P/E Ratio | ★ $17.33 | $111.36 |
| Revenue Growth | 0.92 | ★ 99.97 |
| 52 Week Low | $33.70 | $61.96 |
| 52 Week High | $49.41 | $150.44 |
| Indicator | SLGN | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 30.16 |
| Support Level | $36.83 | $66.44 |
| Resistance Level | $41.87 | $97.18 |
| Average True Range (ATR) | 1.18 | 6.58 |
| MACD | -0.30 | -2.77 |
| Stochastic Oscillator | 10.78 | 10.93 |
Silgan Holdings Inc is a manufacturer of sustainable rigid packaging solutions for the world's essential consumer goods products. Its products include: dispensing and specialty closures for fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden products; steel and aluminum containers for pet and human food and general line products; and custom designed plastic containers for pet and human food, consumer health and pharmaceutical, personal care, home care, lawn and garden and automotive products.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.